




## State SLEEP Conference

Presented by

**YaleCME**  
CONTINUING MEDICAL EDUCATION

Yale School of Medicine's Department of Internal Medicine, Section of Pulmonary, Critical Care, & Sleep Medicine

# Joint Yale-Harvard Sleep Conference: New and Upcoming Drugs for Hypersomnolence Disorders



## Thomas E Scammell, MD

Professor of Neurology, Harvard Medical School  
Professor, Dept of Neurology, Beth Israel Deaconess Medical Center  
Chief, Sleep Medicine Division, Beth Israel Deaconess Medical Center

### Wednesday, February 12, 2020 @ 2-3 pm

The Anlyan Center, TAC S-447

**Moderator: Andrey Zinchuk, MD**

There is no corporate support for this activity. This course will fulfill the licensure requirement set forth by the State of Connecticut

#### ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

#### TARGET AUDIENCE

Attending physicians, house staff/fellows, medical students, nurses, physician assistants.

#### NEEDS ASSESSMENT

In the last year, new medications for treating sleepiness have become available, and many more are under development. This lecture will focus on these advances, enabling clinicians to prescribe medications more thoughtfully.

#### LEARNING OBJECTIVES

At the conclusion of this talk, individuals will:

1. Review basic pharmacology of wakefulness and sleep
2. Learn about newly available medications for treating sleepiness
3. Become familiar with medications that should be available in the next few years

#### DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1 *AMA PRA Category 1 Credit(s)*<sup>TM</sup>. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

#### FACULTY DISCLOSURES

Lauren Tobias, MD, Course Director – No conflicts of interest  
Thomas E Scammell, MD – Alkermes, Avadel Pharmaceuticals, Harmony Biosciences, Jazz Pharmaceuticals, Merck, Suven Life Sciences, Takeda, Umeocrine Cognition

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity, and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.